Terms: = Thyroid cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE
38 results:
1. Clinical features and therapeutic outcomes of GH/TSH cosecreting pituitary adenomas: experience of a single pituitary center.
Yu N; Duan L; Hu F; Yang S; Liu J; Chen M; Yao Y; Deng K; Feng F; Lian X; Mao X; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1197244. PubMed ID: 37324275
[TBL] [Abstract] [Full Text] [Related]
2. Correlation of DNA methylation and lymph node metastasis in papillary thyroid carcinoma.
Zhao F; Zhu S; Fang J; Dong H; Zhu C
Head Neck; 2023 Jul; 45(7):1654-1662. PubMed ID: 37097909
[TBL] [Abstract] [Full Text] [Related]
3. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
[TBL] [Abstract] [Full Text] [Related]
4. Antitumor Effect of Morusin via G1 Arrest and Antiglycolysis by AMPK Activation in Hepatocellular cancer.
Cho AR; Park WY; Lee HJ; Sim DY; Im E; Park JE; Ahn CH; Shim BS; Kim SH
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638959
[TBL] [Abstract] [Full Text] [Related]
5. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract] [Full Text] [Related]
6. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract] [Full Text] [Related]
7. MiR-128-3p suppresses breast cancer cellular progression via targeting LIMK1.
Zhao J; Li D; Fang L
Biomed Pharmacother; 2019 Jul; 115():108947. PubMed ID: 31078043
[TBL] [Abstract] [Full Text] [Related]
8. LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/cdk6 axis.
Zhang H; Zhao B; Wang X; Zhang F; Yu W
Life Sci; 2019 Jul; 228():135-144. PubMed ID: 31047896
[TBL] [Abstract] [Full Text] [Related]
9. [Study on the mechanism of miR-497-induced laryngeal squamous cell carcinoma growth inhibition by targeting cdk6].
Niu JT; Liu SG; Yan P; Li C
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 54(2):126-132. PubMed ID: 30776865
[No Abstract] [Full Text] [Related]
10. Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma.
Ko JJ; Grewal JK; Ng T; Lavoie JM; Thibodeau ML; Shen Y; Mungall AJ; Taylor G; Schrader KA; Jones SJM; Kollmannsberger C; Laskin J; Marra MA
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30446580
[TBL] [Abstract] [Full Text] [Related]
11. Dermatopontin inhibits papillary thyroid cancer cell proliferation through MYC repression.
Guo Y; Li H; Guan H; Ke W; Liang W; Xiao H; Li Y
Mol Cell Endocrinol; 2019 Jan; 480():122-132. PubMed ID: 30391671
[TBL] [Abstract] [Full Text] [Related]
12. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract] [Full Text] [Related]
13. KIAA0101 inhibition suppresses cell proliferation and cell cycle progression by promoting the interaction between p53 and Sp1 in breast cancer.
Lv W; Su B; Li Y; Geng C; Chen N
Biochem Biophys Res Commun; 2018 Sep; 503(2):600-606. PubMed ID: 29902451
[TBL] [Abstract] [Full Text] [Related]
14. The effects of the Union for International cancer Control/American Joint Committee on cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.
Verburg FA; Mäder U; Luster M; Reiners C
Clin Endocrinol (Oxf); 2018 Jun; 88(6):950-956. PubMed ID: 29573277
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of pain during high-intensity focused ultrasound ablation of benign thyroid nodules.
Lang BHH; Woo YC; Chiu KW
Eur Radiol; 2018 Jun; 28(6):2620-2627. PubMed ID: 29330630
[TBL] [Abstract] [Full Text] [Related]
16. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
[TBL] [Abstract] [Full Text] [Related]
17. DIAGNOSING AND MONITORING ENDOCRINE DYSFUNCTION, DIABETES, AND OBESITY IN A COHORT OF ADULT SURVIVORS OF CHILDHOOD cancer.
Hudspeth VR; Gold SH; Clemmons DR
Endocr Pract; 2017 Dec; 23(12):1394-1401. PubMed ID: 29144813
[TBL] [Abstract] [Full Text] [Related]
18. Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma.
Yang JH; Maciel RMB; Nakabashi CCD; Janovsky CCPS; Padovani RP; Macellaro D; Camacho CP; Osawa A; Wagner J; Biscolla RPM
Arch Endocrinol Metab; 2017; 61(5):416-425. PubMed ID: 28977157
[TBL] [Abstract] [Full Text] [Related]
19. Disparities in the Care of Differentiated thyroid cancer in the United States: Exploring the National cancer Database.
Jaap K; Campbell R; Dove J; Fluck M; Hunsinger M; Wild J; Arora T; Shabahang M; Blansfield J
Am Surg; 2017 Jul; 83(7):739-746. PubMed ID: 28738945
[TBL] [Abstract] [Full Text] [Related]
20. Integrative Phosphoproteomics Links IL-23R Signaling with Metabolic Adaptation in Lymphocytes.
Lochmatter C; Fischer R; Charles PD; Yu Z; Powrie F; Kessler BM
Sci Rep; 2016 Apr; 6():24491. PubMed ID: 27080861
[TBL] [Abstract] [Full Text] [Related]
[Next]
